罗氏(RHHBY.US)将重新在市场上销售新版雷珠单抗植入剂

智通财经07-09

智通财经APP获悉，7月8日，罗氏(RHHBY.US)宣布FDA已批准Susvimo(雷珠单抗植入剂，规格：100mg/mL)的生物制品许可申请(BLA)的批准后补充，该补充文件更新了对Susvimo的眼部植入物和再填充针的组件说明。近期，罗氏将重新在市场上销售新版Susvimo。此时距离Susvimo暂时撤出市场已过去近两年。据了解，Susvimo是罗氏为实现缓释以减轻患者多次眼部注射雷珠单抗的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2450044724?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-09 20:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2450044724","market":"us","top_or_hot":-1,"title":"罗氏(RHHBY.US)将重新在市场上销售新版雷珠单抗植入剂","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，7月8日，罗氏(RHHBY.US)宣布FDA已批准Susvimo(雷珠单抗植入剂，规格：100mg/mL)的生物制品许可申请(BLA)的批准后补充，该补充文件更新了对Susvimo的眼部植入物和再填充针的组件说明。近期，罗氏将重新在市场上销售新版Susvimo。此时距离Susvimo暂时撤出市场已过去近两年。据了解，Susvimo是罗氏为实现缓释以减轻患者多次眼部注射雷珠单抗的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1148186.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>罗氏(RHHBY.US)将重新在市场上销售新版雷珠单抗植入剂</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n罗氏(RHHBY.US)将重新在市场上销售新版雷珠单抗植入剂\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-09 20:47 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1148186.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，7月8日，罗氏(RHHBY.US)宣布FDA已批准Susvimo(雷珠单抗植入剂，规格：100mg/mL)的生物制品许可申请(BLA)的批准后补充，该补充文件更新了对Susvimo的眼部植入物和再填充针的组件说明。近期，罗氏将重新在市场上销售新版Susvimo。此时距离Susvimo暂时撤出市场已过去近两年。据了解，Susvimo是罗氏为实现缓释以减轻患者多次眼部注射雷珠单抗的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1148186.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03165","symbol_name":"华夏欧优股对冲","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1148186.html","article_id":"2450044724","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2450044724","pubTimestamp":1720529277,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，7月8日，罗氏宣布FDA已批准Susvimo的生物制品许可申请的批准后补充，该补充文件更新了对Susvimo的眼部植入物和再填充针的组件说明。近期，罗氏将重新在市场上销售新版Susvimo。此时距离Susvimo暂时撤出市场已过去近两年。据了解，Susvimo是罗氏为实现缓释以减轻患者多次眼部注射雷珠单抗的痛苦而开发的一款剂型创新产品，其通过港式给药系统持续向患者眼内递送雷珠单抗，一年仅需植入两次。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"03165":"华夏欧优股对冲","RHHBY":"罗氏控股","BK4007":"制药"},"translate_title":"Roche (RHHBY.US) will re-market the new version of ranibizumab implant","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHHBY":1,"03165":0.6},"content_text":"智通财经APP获悉，7月8日，罗氏(RHHBY.US)宣布FDA已批准Susvimo(雷珠单抗植入剂，规格：100mg/mL)的生物制品许可申请(BLA)的批准后补充，该补充文件更新了对Susvimo的眼部植入物和再填充针的组件说明。近期，罗氏将重新在市场上销售新版Susvimo。此时距离Susvimo暂时撤出市场已过去近两年。据了解，Susvimo是罗氏为实现缓释以减轻患者多次眼部注射雷珠单抗的痛苦而开发的一款剂型创新产品，其通过港式给药系统(Port Delivery Platform)持续向患者眼内递送雷珠单抗，一年仅需植入两次。目前，全球共8款抗VEGF疗法获批用于治疗wAMD，包括培加他尼、布西珠单抗、康柏西普、法瑞西单抗、阿柏西普(2mg)、阿柏西普HD(8mg)、雷珠单抗和Susvimo。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2450044724"}